• Imprimeix

Unitat d'Infeccions i Càncer (UNIC)

L’objectiu de la UNIC és identificar l’etiologia infecciosa del càncer humà. L’àrea principal d’estudi de la UNIC és el virus del papil·loma humà (VPH) i malalties relacionades. Dins de la UNIC molts estudis es dediquen a comprendre la càrrega, la història natural i la prevenció de les malalties relacionades amb el VPH. Junt amb el laboratori de la UNIC, una de les activitats principals és la identificació de VPH en grans sèries internacionals de tumors amb l’objectiu de descriure la distribució mundial de genotips de VPH.

La UNIC té també projectes d'investigació sobre els factors de risc infecciosos, hormonals i la genètica de limfomes, leucèmia limfocítica crònica i mieloma múltiple. El Centre d'Informació participa en diversos estudis de casos-controls multicèntrics com MCC Espanya, EPILYMPH, ICGC-CLL i consorcis InterLymph. La unitat gestiona i s’encarrega de la coordinació del protocol, el seguiment i l’avaluació de les activitats de detecció del càncer de coll d’úter cèrvix en els centres d’Atenció Primària de salut a Catalunya.

Els seus principals estudis estan relacionats amb:
1. Estudis sobre càncer genital i virus del papil·loma humà (VPH) i de prevenció mitjançant vacunacions específiques.
2. Estudis sobre l’etiologia infecciosa dels limfomes malignes.
3. Estudis sobre factors de risc infecciosos, genètics i mediambientals vinculats al desenvolupament de limfomes.
4. La susceptibilitat genètica i la interacció entre gens i medi ambient. Estudis etiològics sobre els càncers de cèrvix, de cavitat oral, faringe, laringe, vagina, vulva, penis i càncer d’anus.
5. Investigacions en temes de modelització i d’avaluació econòmica de les mesures de prevenció del càncer a Espanya i d’altres països. Estudis sobre el càncer de pròstata (en preparació).
6. Centre ICO d'Informació del VPH i malalties relacionades.
7. Desenvolupament d’instruments logístics per a la coordinació i difusió de la informació sobre virus i càncer.
8. Cribratge i prevenció del càncer cervical.
9. Les proves clíniques de les vacunes contra el VPH i l’avaluació de l'impacte dels programes de vacunació contra el VPH.

• Virus del Papil·loma Humà (VPH) i càncer genital.
• VPH i càncer en cap i coll.
• Virus hepatotròpics, EBV, poliomes i càncer.
• Assajos de vacunació contra VPH i els estudis d’intervenció en la prevenció del càncer.
• Factors etiològics relacionats amb limfomes malignes.
• Centre ICO d’Informació sobre el VPH i les malalties relacionades.
• Detecció i prevenció del càncer genital.
• Avaluació de les tecnologies de detecció viral.
• Modelització i avaluació econòmica de les mesures de prevenció del càncer.

  1. Gillison ML, Castellsagué X, Chaturvedi A, Goodman MT, Snijders P, Tommasino M, Arbyn M, Franceschi S. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer. 2014 Feb 1;134(3):497-507. doi: 10.1002/ijc.28201. Impact Factor: 6.198. Q1: Oncology.
  2. Lubin JH, De Stefani E, Abnet CC, Acosta G, Boffetta P, Victora C, Graubard BI, Muñoz N, Deneo-Pellegrini H, Franceschi S, Castellsagué X, Ronco AL, Dawsey SM. Mate drinking and esophageal squamous cell carcinoma in South america: pooled results from two large multicenter case-control studies. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):107-16. doi: 10.1158/1055-9965.EPI-13-0796. Epub 2013 Oct 15. PubMed PMID: 24130226. Impact Factor: 4.559. Q1: Public, Environmental & Occupational Health.
  3. Poljak M, Rogovskaya SI, Kesić V, Bray F, Berkhof J, Seme K, Brotons M, Castellsagué X, Syrjänen S, Arbyn M, Bosch FX. Recommendations for cervical cancer prevention in central and eastern europe and central Asia. Vaccine. 2013 Dec 31;31 Suppl 7:H80-2. doi: 10.1016/j.vaccine.2013.04.038. PubMed PMID: 24332300. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  4. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Díaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Dec 31;31 Suppl 7:H1-H31. doi: 10.1016/j.vaccine.2013.10.003. PubMed PMID: 24332295. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  5. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Díaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Dec 30;31 Suppl 6:G1-G31. doi: 10.1016/j.vaccine.2013.10.002. PubMed PMID: 24331817. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  6. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Díaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Dec 29;31 Suppl 5:F1-F31. doi: 10.1016/j.vaccine.2013.10.001. PubMed PMID: 24331745. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  7. Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, Bosch FX, de Sanjosé S, Dillner J, Gram IT, Tjønneland A, Munk C, Pala V, Palli D, Khaw KT, Barnabas RV, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fagherazzi G, Kaaks R, Lukanova A, Steffen A, Trichopoulou A, Trichopoulos D, Klinaki E, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita HB, Peeters PH, Lund E, Weiderpass E, Redondo ML, Sánchez MJ, Tormo MJ, Barricarte A, Larrañaga N, Ekström J, Hortlund M, Lindquist D, Wareham N, Travis RC, Rinaldi S, Tommasino M, Franceschi S, Riboli E. Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. Int J Cancer. 2013 Dec 13. doi: 10.1002/ijc.28666. [Epub ahead of print] PubMed PMID: 24338632. Impact Factor: 6.198. Q1: Oncology.
  8. Castellsagué X, Pawlita M, Roura E, Margall N, Waterboer T, Bosch FX, de Sanjosé S, Gonzalez CA, Dillner J, Gram IT, Tjønneland A, Munk C, Pala V, Palli D, Khaw KT, Barnabas RV, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fagherazzi G, Kaaks R, Lukanova A, Steffen A, Trichopoulou A, Trichopoulos D, Klinaki E, Tumino R, Sacerdote C, Mattiello A, Bueno-de-Mesquita HB, Peeters PH, Lund E, Weiderpass E, Quirós JR, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Hortlund M, Lindquist D, Wareham N, Travis RC, Rinaldi S, Tommasino M, Franceschi S, Riboli E. Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort. Int J Cancer. 2013 Dec 13. doi: 10.1002/ijc.28665. [Epub ahead of print] PubMed PMID: 24338606. Impact Factor: 6.198. Q1: Oncology.
  9. Lee YC, Zugna D, Richiardi L, Merletti F, Marron M, Ahrens W, Pohlabeln H, Lagiou P, Trichopoulos D, Agudo A, Castellsagué X, Betka J, Holcatova I, Kjaerheim K, Macfarlane GJ, Macfarlane TV, Talamini R, Barzan L, Canova C, Simonato L, Conway DI, McKinney PA, Thomson P, Znaor A, Healy CM, McCartan BE, Boffetta P, Brennan P, Hashibe M. Smoking addiction and the risk of upper-aerodigestive-tract cancer in a multicenter case-control study. Int J Cancer. 2013 Dec 1;133(11):2688-95. doi: 10.1002/ijc.28288. Epub 2013 Jun 21. PubMed PMID: 23719996. Impact Factor: 6.198. Q1: Oncology.
  10. Alemany L, de Sanjosé S, Tous S, Quint W, Vallejos C, Shin HR, Bravo LE, Alonso P, Lima MA, Guimerà N, Klaustermeier J, Llombart-Bosch A, Kasamatsu E, Tatti SA, Felix A, Molina C, Velasco J, Lloveras B, Clavero O, Lerma E, Laco J, Bravo IG, Guarch R, Pelayo A, Ordi J, Andújar M, Sanchez GI, Castellsagué X, Muñoz N, Bosch FX; on Behalf of the RIS HPV TT Study Group. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer. 2013 Nov 28. doi: 10.1002/ijc.28636. [Epub ahead of print] PubMed PMID: 24382655. Impact Factor: 6.198. Q1: Oncology.
  11. Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N. Estimation of the potential overall impact of human papillomavirus vaccination on cervical càncer cases and deaths. Vaccine. 2013 Nov 26. pii: S0264-410X(13)01583-1. doi: 10.1016/j.vaccine.2013.11.049. [Epub ahead of print] PubMed PMID: 24291200. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  12. Leoncini E, Ricciardi W, Cadoni G, Arzani D, Petrelli L, Paludetti G, Brennan, Luce D, Stucker I, Matsuo K, Talamini R, La Vecchia C, Olshan AF, Winn DM, Herrero R, Franceschi S, Castellsagué X, Muscat J, Morgenstern H, Zhang ZF, Levi F, Dal Maso L, Kelsey K, McClean M, Vaughan TL, Lazarus P, Purdue MP, Hayes RB, Chen C, Schwartz SM, Shangina O, Koifman S, Ahrens W, Matos E, Lagiou P, Lissowska J, Szeszenia-Dabrowska N, Fernandez L, Menezes A, Agudo A, Daudt AW, Richiardi L, Kjaerheim K, Mates D, Betka J, Yu GP, Schantz S, Simonato L, Brenner H, Conway DI, Macfarlane TV, Thomson P, Fabianova E, Znaor A, Rudnai P, Healy C, Boffetta P, Chuang SC, Lee YC, Hashibe M, Boccia S. Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. Eur J Epidemiol. 2013 Nov 24. [Epub ahead of print] PubMed PMID: 24271556. Impact Factor: 5.118. Q1: Public, Environmental & Occupational Health.
  13. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Díaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. PubMed PMID: 24229716. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  14. de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, Vidal A, Guimerà N, Cross P, Wain GV, Petry KU, Mariani L, Bergeron C, Mandys V, Sica AR, Félix A, Usubutun A, Seoud M, Hernández-Suárez G, Nowakowski AM, Wilson G, Dalstein V, Hampl M, Kasamatsu ES, Lombardi LE, Tinoco L, Alvarado-Cabrero I, Perrotta M, Bhatla N, Agorastos T, Lynch CF, Goodman MT, Shin HR, Viarheichyk H, Jach R, Cruz MO, Velasco J, Molina C, Bornstein J, Ferrera A, Domingo EJ, Chou CY, Banjo AF, Castellsagué X, Pawlita M, Lloveras B, Quint WG, Muñoz N, Bosch FX; HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013 Nov;49(16):3450-61. doi:10.1016/j.ejca.2013.06.033. Epub 2013 Jul 22. PubMed PMID: 23886586. Impact Factor: 5.061. Q1: Oncology.
  15. Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013 Nov 1;208(9):1391-6. doi: 10.1093/infdis/jit360. PubMed PMID: 24092907; PubMed Central PMCID: PMC3789574. Impact Factor: 5.848. Q1: Immunology.
  16. Evans DM, Brion MJ, Paternoster L, Kemp JP, McMahon G, Munafò M, Whitfield JB, Medland SE, Montgomery GW; GIANT Consortium; CRP Consortium; TAG Consortium, Timpson NJ, St Pourcain B, Lawlor DA, Martin NG, Dehghan A, Hirschhorn J, Davey Smith G. (Collaborators : Castellsagué X). Mining the human phenome using allelic scores that index biological intermediates. PLoS Genet. 2013 Oct;9(10):e1003919. doi: 10.1371/journal.pgen.1003919. Epub 2013 Oct 31. PubMed PMID: 24204319; PubMed Central PMCID: PMC3814299. Impact Factor: 8.517. Q1: Genetics & Heredity.
  17. Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U, Thorleifsson G, Walters GB; TAG Consortium; Oxford-GSK Consortium; ENGAGE consortium, Furberg H, Sullivan PF, Marchini J, McCarthy MI, Steinthorsdottir V, Thorsteinsdottir U, Stefansson K. (Collaborators: Agudo A, Castellsagué X). A common biological basis of obesity and nicotine addiction. Transl Psychiatry. 2013 Oct 1;3:e308. doi:10.1038/tp.2013.81. PubMed PMID: 24084939; PubMed Central PMCID: PMC3818010.
  18. Wyss A, Hashibe M, Chuang SC, Lee YC, Zhang ZF, Yu GP, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Smith E, Shangina O, Schwartz SM, Schantz S, Rudnai P, Purdue MP, Eluf-Neto J, Muscat J, Morgenstern H, Michaluart P Jr, Menezes A, Matos E, Mates IN, Lissowska J, Levi F, Lazarus P, La Vecchia C, Koifman S, Herrero R, Hayes RB, Franceschi S, Wünsch-Filho V, Fernandez L, Fabianova E, Daudt AW, Dal Maso L, Curado MP, Chen C, Castellsagué X, de Carvalho MB, Cadoni G, Boccia S, Brennan P, Boffetta P, Olshan AF. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol. 2013 Sep 1;178(5):679-90. doi: 10.1093/aje/kwt029. Epub 2013 Jun 30. PubMed PMID: 23817919; PubMed Central PMCID: PMC3755640. Impact Factor: 4.780. Q1: Public, Environmental & Occupational Health.
  19. Ndiaye C, Alemany L, Diop Y, Ndiaye N, Diémé MJ, Tous S, Klaustermeier JE, Alejo M, Castellsagué X, Bosch FX, Trottier H, de Sanjosé S. The role of human papillomavirus in head and neck cancer in Senegal. Infect Agent Cancer. 2013 Apr 17;8(1):14. doi: 10.1186/1750-9378-8-14. PubMed PMID: 23594504; PubMed Central PMCID: PMC3637397.
  20. Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, Gaborieau V, Marron M, Lagiou P, Ahrens W, Holcátová I, Merletti F, Kjaerheim K, Talamini R, Simonato L, Castellsagué X, Macfarlane TV, Biggs AM, Thakker N, Znaor A, Thomson P, Canova C, Conway DI, Healy CM, Tommasino M, Pawlita M, Brennan P. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst. 2013 Apr 17;105(8):536-45. doi: 10.1093/jnci/djt053. Epub 2013 Mar 16. PubMed PMID: 23503618. Impact Factor: 14.336. Q1: Oncology.
  21. Sharma M, Bruni L, Díaz M, Castellsagué X, de Sanjosé S, Bosch FX, Kim JJ. Using HPV prevalence to predict cervical cancer incidence. Int J Cancer. 2013 Apr 15;132(8):1895-900. doi: 10.1002/ijc.27835. Epub 2012 Oct 11. PubMed PMID: 22965284. Impact Factor: 6.198. Q1: Oncology.
  22. Schork AJ, Thompson WK, Pham P, Torkamani A, Roddey JC, Sullivan PF, Kelsoe JR, O'Donovan MC, Furberg H; Tobacco and Genetics Consortium; Bipolar Disorder Psychiatric Genomics Consortium; Schizophrenia Psychiatric Genomics Consortium, Schork NJ, Andreassen OA, Dale AM. (Collaborators: Agudo A, Castellsagué X). All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genet. 2013 Apr;9(4):e1003449. doi: 10.1371/journal.pgen.1003449. Epub 2013 Apr 25. PubMed PMID: 23637621; PubMed Central PMCID: PMC3636284. Impact Factor: 8.517. Q1: Genetics & Heredity.
  23. Albero G, Villa LL, Lazcano-Ponce E, Fulp W, Papenfuss MR, Nyitray AG, Lu B, Castellsagué X, Abrahamsen M, Smith D, Bosch FX, Salmerón J, Quiterio M, Giuliano AR. Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis. 2013 Jan 17;13:18. doi: 10.1186/1471-2334-13-18. PubMed PMID: 23327450; PubMed Central PMCID: PMC3554597. Impact Factor: 3.025. Q2: Infectious Diseases.
  24. Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat MC, Descamps D, Struyf F, Dubin GO, Rosillon D, Baril L; HPV PATRICIA Study Group. Correction: Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. PLoS One. 2013 Dec 31;8(12). doi: 10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a. eCollection 2013. PubMed PMID: 24391698; PubMed Central PMCID: PMC3878864. Impact Factor: 3.730. Q2: Multidisciplinary Sciences.
  25. Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat MC, Descamps D, Struyf F, Dubin GO, Rosillon D, Baril L; HPV PATRICIA Study Group. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013 Nov 19;8(11):e79260. doi: 10.1371/journal.pone.0079260. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a. PubMed PMID: 24260180; PubMed Central PMCID: PMC3834039. Impact Factor: 3.730. Q2: Multidisciplinary Sciences.
  26. Bosch FX; Editors. The path to eliminate cervical cancer in the world and the challenges of professional education. Vaccine. 2013 Dec 31;31 Suppl 7:xi-xii. doi: 10.1016/j.vaccine.2013.10.008. PubMed PMID: 24332302. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  27. Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, Lamontagne DS, Albero G, Bosch FX. Extended middle East and north Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer. Vaccine. 2013 Dec 30;31 Suppl 6:G78-9. doi: 10.1016/j.vaccine.2012.11.078. PubMed PMID: 24331823. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  28. Bosch FX; Editors. The path to eliminate cervical cancer in the world and the challenges of professional education. Vaccine. 2013 Dec 29;31 Suppl 5:xi-xii. doi: 10.1016/j.vaccine.2013.10.006. PubMed PMID: 24331752. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  29. Denny LA, Sankaranarayanan R, De Vuyst H, Kim JJ, Adefuye PO, Alemany L, Adewole IF, Awolude OA, Parham G, de Sanjosé S, Bosch FX. Recommendations for cervical cancer prevention in sub-saharan Africa. Vaccine. 2013 Dec 29;31 Suppl 5:F73-4. doi: 10.1016/j.vaccine.2012.11.077. PubMed PMID: 24331750. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  30. Bornstein J, Fisher WA, Ginsberg GM, Shavit O, Schejter E, Díaz M, Bosch FX. Screening for cervical cancer and human papillomavirus vaccination in Israel: recommendations. Vaccine. 2013 Nov 22;31 Suppl 8:I58-60. doi: 10.1016/j.vaccine.2013.07.048. PubMed PMID: 24229721. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  31. Godínez JM, Nicolás-Párraga S, Pimenoff VN, Mengual-Chuliá B, Muñoz N, Bosch FX, Sánchez GI, McCloskey J, Bravo IG. Phylogenetically related, clinically different: human papillomaviruses 6 and 11 variants distribution in genital warts and in laryngeal papillomatosis. Clin Microbiol Infect. 2013 Oct 5. doi: 10.1111/1469-0691.12420. [Epub ahead of print] PubMed PMID: 24118667. Impact Factor: 4.578. Q1: Infectious Diseases.
  32. Guimerà N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, Hernández-Suárez G, Bravo IG, Molijn A, Jenkins D, Cubilla A, Muñoz N, de Sanjosé S, Bosch FX, Quint W; RIS HPV TTHPV VVAPO study groups. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol. 2013 Sep;37(9):1299-310. doi:10.1097/PAS.0b013e31828b6be4. PubMed PMID: 24076770. Impact Factor: 4.868. Q1: Pathology.
  33. Guimerà N, Lloveras B, Alemany L, Iljazovic E, Shin HR, Jung-Il S, de Sanjosé S, Jenkins D, Bosch FX, Quint W. Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types. Histopathology. 2013 Aug;63(2):287-92. doi: 10.1111/his.12137. Epub 2013 Jun 3. PubMed PMID: 23730874. Impact Factor: 2.857. Q1: Pathology.
  34. Rodríguez-Salés V, Roura E, Ibañez R, Peris M, Bosch FX, de Sanjosé S. Coverage of Cervical Cancer Screening in Catalonia for the Period 2008-2011 among Immigrants and Spanish-Born Women. Front Oncol. 2013 Dec 20;3:297. doi: 10.3389/fonc.2013.00297. eCollection 2013. PubMed PMID: 24392348; PubMed Central PMCID: PMC3868944.
  35. Godínez JM, Heideman DA, Gheit T, Alemany L, Snijders PJ, Tommasino M, Meijer CJ, de Sanjosé S, Bosch FX, Bravo IG. Differential presence of Papillomavirus variants in cervical cancer: an analysis for HPV33, HPV45 and HPV58. Infect Genet Evol. 2013 Jan;13:96-104. doi: 10.1016/j.meegid.2012.09.011. Epub 2012 Sep 26. PubMed PMID: 23022714. Impact Factor: 2.768. Q2: Infectious Diseases.
  36. Pérez C, Castillo M, Alemany L, Tous S, Klaustermeier J, de Sanjosé S, Velasco J. Evaluation of p16(INK4a) overexpression in a large series of cervical carcinomas: concordance with SPF10-LiPA25 PCR. Int J Gynecol Pathol. 2014 Jan;33(1):74-82. doi: 10.1097/PGP.0b013e3182774546. PubMed PMID: 24300539. Impact Factor: 1.413. Q3: Obstetrics & Gynecology.
  37. Adefuye PO, Broutet NJ, de Sanjosé S, Denny LA. Trials and projects on cervical cancer and human papillomavirus prevention in sub-saharan Africa. Vaccine. 2013 Dec 29;31 Suppl 5:F53-9. doi: 10.1016/j.vaccine.2012.06.070. PubMed PMID: 24331748. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  38. Monnereau A, Glaser SL, Schupp CW, Ekström Smedby K, de Sanjosé S, Kane E, Melbye M, Forétova L, Maynadié M, Staines A, Becker N, Nieters A, Brennan P, Boffetta P, Cocco P, Glimelius I, Clavel J, Hjalgrim H, Chang ET. Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysis. Blood. 2013 Nov 14;122(20):3492-9. doi: 10.1182/blood-2013-04-497586. Epub 2013 Sep 9. PubMed PMID: 24016459; PubMed Central PMCID: PMC3829118. Impact Factor: 9.060. Q1: Hematology.
  39. Torres M, González C, del Romero J, Viciana P, Ocampo A, Rodríguez-Fortúnez P, Masiá M, Blanco JR, Portilla J, Rodríguez C, Hernández-Novoa B, del Amo J, Ortiz M; CoRIS-HPV Study Group. (Col•laboradors: de Sanjosé S). Anal human papillomavirus genotype Distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort. J Clin Microbiol. 2013 Nov;51(11):3512-20. doi: 10.1128/JCM.01405-13. Epub 2013 Aug 21. PubMed PMID: 23966501; PubMed Central PMCID: PMC3889727. Impact Factor: 4.068. Q1: Microbiology.
  40. Cocco P, Vermeulen R, Flore V, Nonne T, Campagna M, Purdue M, Blair A, Monnereau A, Orsi L, Clavel J, Becker N, de Sanjosé S, Foretova L, Staines A, Maynadié M, Nieters A, Miligi L, 't Mannetje A, Kricker A, Brennan P, Boffetta P, Lan Q, Rothman N. Occupational exposure to trichloroethylene and risk of non-Hodgkin lymphoma and its major subtypes: a pooled IinterLlymph analysis. Occup Environ Med. 2013 Nov;70(11):795-802. doi: 10.1136/oemed-2013-101551. Epub 2013 Jul 23. PubMed PMID: 23881218. Impact Factor: 3.215. Q1: Public, Environmental & Occupational Health.
  41. Jacquin E, Baraquin A, Ramanah R, Carcopino X, Morel A, Valmary-Degano S, Bravo IG, de Sanjosé S, Riethmuller D, Mougin C, Prétet JL. Methylation of human papillomavirus Type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR. J Clin Microbiol. 2013 Oct;51(10):3207-15. doi: 10.1128/JCM.01106-13. Epub 2013 Jul 17. PubMed PMID: 23863566; PubMed Central PMCID: PMC3811632. Impact Factor: 4.068. Q1: Microbiology.
  42. Slager SL, Caporaso NE, de Sanjosé S, Goldin LR. Genetic susceptibility to chronic lymphocytic leukemia. Semin Hematol. 2013 Oct;50(4):296-302. doi: 10.1053/j.seminhematol.2013.09.007. PubMed PMID: 24246697; PubMed Central PMCID: PMC3834539. Impact Factor: 3.357. Q2: Hematology.
  43. Andreotti G, Birmann B, De Roos AJ, Spinelli J, Cozen W, Camp NJ, Moysich K, Chiu B, Steplowski E, Krzystan J, Boffetta P, Benhaim-Luzon V, Brennan P, de Sanjosé S, Costas L, Costantini AS, Miligi L, Cocco P, Becker N, Foretová L, Maynadié M, Nieters A, Staines A, Tricot G, Milliken K, Weisenburger D, Zheng T, Baris D, Purdue MP. A pooled analysis of alcohol consumption and risk of múltiple myeloma in the international multiple myeloma consortium. Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1620-7. doi: 10.1158/1055-9965.EPI-13-0334. Epub 2013 Aug 20. PubMed PMID: 23964064; PubMed Central PMCID: PMC3769449. Impact Factor: 4.559. Q1: Public, Environmental & Occupational Health.
  44. González C, Torres M, Benito A, Del Romero J, Rodríguez C, Fontillón M, Trastoy M, Viciana P, Del Amo J, Ortiz M, Hernández-Novoa B; CoRIS-HPV Study Group. Anal squamous intraepithelial lesions are frequent among Young HIV-infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRIS-HPV). (Col•laboradors: de Sanjosé S). Int J Cancer. 2013 Sep 1;133(5):1164-72. doi: 10.1002/ijc.28102. Epub 2013 Mar 7. PubMed PMID: 23404769. Impact Factor: 6.198. Q1: Oncology.
  45. Espinosa A, Zock JP, Benavente Y, Boffetta P, Becker N, Brennan P, Cocco P, Foretova L, Maynadié M, Staines A, Nieters A, Kogevinas M, de Sanjosé S. Occupational exposure to immunologically active agents and risk for lymphoma: the European Epilymph case-control study. Cancer Epidemiol. 2013 Aug;37(4):378-84. doi: 10.1016/j.canep.2013.02.006. Epub 2013 Mar 20. PubMed PMID: 23522435. Impact Factor: 2.232. Q2: Public, Environmental & Occupational Health.
  46. Robles C, Viscidi R, Malats N, Silverman DT, Tardon A, Garcia-Closas R, Serra C, Carrato A, Herranz J, Lloreta J, Rothman N, Real FX, de Sanjosé S, Kogevinas M. Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. Int J Cancer. 2013 Aug 1;133(3):597-603. doi: 10.1002/ijc.28053. Epub 2013 Feb 27. PubMed PMID: 23355322. Impact Factor: 6.198. Q1: Oncology.
  47. Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, Cozen W, Monnereau A, Wang SS, Kelly RS, Lan Q, Teras LR, Chatterjee N, Chung CC, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Armstrong BK, Cocco P, Zhang Y, Severi G, Zeleniuch-Jacquotte A, Lawrence C, Burdette L, Yuenger J, Hutchinson A, Jacobs KB, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Wang AH, Smedby KE, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Jones B, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Holly EA, Smith MT, Jackson RD, Tinker LF, Benavente Y, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Leis JF, Cunningham JM, Weinberg JB, Morrison VA, Caporaso NE, Norman AD, Linet MS, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RC, Travis RC, Giles GG, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Offit K, Zelenetz A, Klein RJ, Spinelli JJ, Bertrand KA, Laden F, Giovannucci E, Kraft P, Kricker A, Turner J, Vajdic CM, Ennas MG, Ferri GM, Miligi L, Liang L, Sampson J, Crouch S, Park JH, North KE, Cox A, Snowden JA, Wright J, Carracedo A, Lopez-Otin C, Bea S, Salaverria I, Martin-Garcia D, Campo E, Fraumeni JF Jr, de Sanjosé S, Hjalgrim H, Cerhan JR, Chanock SJ, Rothman N, Slager SL. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013 Aug;45(8):868-76. doi: 10.1038/ng.2652. Epub 2013 Jun 16. PubMed PMID: 23770605; PubMed Central PMCID: PMC3729927. Impact Factor: 35.209. Q1: Genetics & Heredity.
  48. Watson-Jones D, Baisley K, Brown J, Kavishe B, Andreasen A, Changalucha J, Mayaud P, Kapiga S, Gumodoka B, Hayes RJ, de Sanjosé S. High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. Sex Transm Infect. 2013 Aug;89(5):358-65. doi: 10.1136/sextrans-2012-050685. Epub 2013 Mar 13. PubMed PMID: 23486859; PubMed Central PMCID: PMC3717757. Impact Factor: 2.611. Q1: Infectious Diseases.
  49. Chaux A, Netto GJ, Rodríguez IM, Barreto JE, Oertell J, Ocampos S, Boggino H, Codas R, Bosch FX, de Sanjosé S, Muñoz N, Hildesheim A, Cubilla AL. Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol. 2013 Aug;31(4):861-7. doi: 10.1007/s00345-011-0802-0. Epub 2011 Nov 25. PubMed PMID: 22116602; PubMed Central PMCID: PMC3292668. Impact Factor: 2.888. Q1: Urology & Nephrology.
  50. de Sanjosé S, Wheeler CM, Quint WG, Hunt WC, Joste NE, Alemany L, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group, Myers ER, Castle PE. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1313-8. doi: 10.1158/1055-9965.EPI-13-0053. Epub 2013 Apr 30. PubMed PMID: 23632816. Impact Factor: 4.559. Q1: Public, Environmental & Occupational Health.
  51. Perrotta C, Kleefeld S, Staines A, Tewari P, De Roos AJ, Baris D, Birmann B, Chiu B, Cozen W, Becker N, Foretova L, Maynadié M, Nieters A, de Sanjosé S, Miligi L, Seniori Costantini A, Purdue M, Spinelli J, Cocco P. Multiple mieloma and occupation: a pooled analysis by the International Multiple Myeloma Consortium. Cancer Epidemiol. 2013 Jun;37(3):300-5. doi: 10.1016/j.canep.2013.01.008. Epub 2013 Feb 9. PubMed PMID: 23403129. Impact Factor: 2.232. Q2: Public, Environmental & Occupational Health.
  52. Hall JS, Iype R, Armenoult LS, Taylor J, Miller CJ, Davidson S, de Sanjosé S, Bosch FX, Stern PL, West CM. Poor prognosis associated with human papillomavirus α7 genotypes in cervical carcinoma cannot be explained by intrinsic radiosensitivity. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e223-9. doi: 10.1016/j.ijrobp.2012.11.030. Epub 2013 Jan 17. PubMed PMID: 23332225. Impact Factor: 4.524. Q1: Oncology.
  53. Costas L, Kogevinas M, de Sanjosé S. Comment on: 'Second to fourth dígit ratio (2D:4D), breast cancer risk factors, and breast cancer risk: a prospective cohort study'. Br J Cancer. 2013 Feb 19;108(3):742. doi: 10.1038/bjc.2012.530. Epub 2012 Nov 27. PubMed PMID: 23187821; PubMed Central PMCID: PMC3593534. Impact Factor: 5.082. Q1: Oncology.
  54. Cocco P, Satta G, Dubois S, Pili C, Pilleri M, Zucca M, 't Mannetje AM, Becker N, Benavente Y, de Sanjosé S, Foretova L, Staines A, Maynadié M, Nieters A, Brennan P, Miligi L, Ennas MG, Boffetta P. Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study. Occup Environ Med. 2013 Feb;70(2):91-8. doi: 10.1136/oemed-2012-100845. Epub 2012 Nov 1. PubMed PMID:23117219. Impact Factor: 3.215. Q1: Public, Environmental & Occupational Health.
  55. Gibson TM, Smedby KE, Skibola CF, Hein DW, Slager SL, de Sanjosé S, Vajdic CM, Zhang Y, Chiu BC, Wang SS, Hjalgrim H, Nieters A, Bracci PM, Kricker A, Zheng T, Kolar C, Cerhan JR, Darabi H, Becker N, Conde L, Holford TR, Weisenburger DD, De Roos AJ, Butterbach K, Riby J, Cozen W, Benavente Y, Palmers C, Holly EA, Sampson JN, Rothman N, Armstrong BK, Morton LM. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes Control. 2013 Jan;24(1):125-34. doi: 10.1007/s10552-012-0098-4. Epub 2012 Nov 18. PubMed PMID: 23160945; PubMed Central PMCID: PMC3529854. Impact Factor: 3.200. Q1: Public, Environmental & Occupational Health.
  56. Casabonne D, Almeida J, Nieto WG, Romero A, Fernández-Navarro P, Rodriguez-Caballero A, Muñoz-Criado S, Díaz MG, Benavente Y, de Sanjosé S, Orfao A; the Primary Health Care Group of Salamanca for the Study of MBL. Correction: Common Infectious Agents and Monoclonal B-Cell Lymphocytosis: A Cross-Sectional Epidemiological Study among Healthy Adults. PLoS One. 2013 Oct 11;8(10). doi: 10.1371/annotation/6f57f3c7-2f86-4d3a-a646-cb54de56ddba. eCollection 2013. PubMed PMID: 24146721; PubMed Central PMCID: PMC3795778. Impact Factor: 3.730. Q2: Multidisciplinary Sciences.
  57. Kamper-Jørgensen M, Rostgaard K, Glaser SL, Zahm SH, Cozen W, Smedby KE, de Sanjosé S, Chang ET, Zheng T, La Vecchia C, Serraino D, Monnereau A, Kane EV, Miligi L, Vineis P, Spinelli JJ, McLaughlin JR, Pahwa P, Dosman JA, Vornanen M, Foretova L, Maynadie M, Staines A, Becker N, Nieters A, Brennan P, Boffetta P, Cocco P, Hjalgrim H. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol. 2013 Sep;24(9):2245-55. doi: 10.1093/annonc/mdt218. Epub 2013 Jun 19. PubMed PMID: 23788758; PubMed Central PMCID: PMC3755332. Impact Factor: 7.384. Q1: Oncology.
  58. Cocco P, Satta G, D'Andrea I, Nonne T, Udas G, Zucca M, Mannetje A, Becker N, de Sanjosé S, Foretova L, Staines A, Maynadié M, Nieters A, Brennan P, Ennas MG, Boffetta P. Lymphoma risk in livestock farmers: results of the Epilymph study. Int J Cancer. 2013 Jun 1;132(11):2613-8. doi: 10.1002/ijc.27908. Epub 2012 Nov 2. PubMed PMID: 23065666. Impact Factor: 6.198. Q1: Oncology.
  59. Kane EV, Bernstein L, Bracci PM, Cerhan JR, Costas L, Dal Maso L, Holly EA, La Vecchia C, Matsuo K, de Sanjosé S, Spinelli JJ, Wang SS, Zhang Y, Zheng T, Roman E, Kricker A; InterLymph Consortium. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. Ann Oncol. 2013 Feb;24(2):433-41. doi: 10.1093/annonc/mds340. Epub 2012 Sep 11. PubMed PMID: 22967995; PubMed Central PMCID: PMC3551484. Impact Factor: 7.384. Q1: Oncology.
  60. García-Pérez R, Ibáñez C, Godínez JM, Aréchiga N, Garin I, Pérez-Suárez G, de Paz O, Juste J, Echevarría JE, Bravo IG. Novel Papillomaviruses in Free-Ranging Iberian Bats: No Virus-Host Co-evolution, No Strict Host Specificity, and Hints for Recombination. Genome Biol Evol. 2014 Jan;6(1):94-104. doi: 10.1093/gbe/evt211. PubMed PMID: 24391150. Impact Factor: 4.759. Q1: Genetics & Heredity.
  61. García-Pérez R, Gottschling M, Wibbelt G, Bravo IG. Multiple evolutionary origins of bat papillomaviruses. Vet Microbiol. 2013 Jul 26;165(1-2):51-60. doi: 10.1016/j.vetmic.2013.01.009. Epub 2013 Feb 5. PubMed PMID: 23481575. Impact Factor: 3.127. Q2: Microbiology.
  62. Shavit O, Roura E, Barchana M, Díaz M, Bornstein J. Burden of human papillomavirus infection and related diseases in Israel. Vaccine. 2013 Nov 22;31 Suppl 8:I32-41. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  63. Berkhof J, Bogaards JA, Demirel E, Díaz M, Sharma M, Kim JJ. Cost-effectvineness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine 2013, vol. 31 suppl. 7: H71-9. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  64. Kim J, Sharma M, O’Shea M, Sweet S, Díaz M, Sancho-Garnier H, Seoud M. Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in the Extended Middle East and North Africa (EMENA). Vaccine 2013, vol. 31 suppl. 6: G65-77. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  65. Kim J, Campos NG, O’Shea M, Díaz M, Mutyaba I. Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa. Vaccine 2013, vol. 31 suppl. 5: F60-72. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  66. Servitje O, Muniesa C, Benavente Y, Monsálvez V, Garcia-Muret MP, Gallardo F, Domingo-Doménech E, Lucas A, Climent F, Rodríguez-Peralto JL, Ortiz-Romero PL, Sandoval J, Pujol RM, Estrach MT. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. J Am Acad Dermatol. 2013 Sep;69(3):357-65. doi: 10.1016/j.jaad.2013.04.047. Epub 2013 Jun 21. PubMed PMID: 23796549. Impact Factor: 4.906. Q1: Dermatology.
  67. Gibson TM, Smedby KE, Skibola CF, Hein DW, Slager SL, de Sanjosé S, Vajdic CM, Zhang Y, Chiu BC, Wang SS, Hjalgrim H, Nieters A, Bracci PM, Kricker A, Zheng T, Kolar C, Cerhan JR, Darabi H, Becker N, Conde L, Holford TR, Weisenburger DD, De Roos AJ, Butterbach K, Riby J, Cozen W, Benavente Y, Palmers C, Holly EA, Sampson JN, Rothman N, Armstrong BK, Morton LM. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes Control. 2013 Jan;24(1):125-34. doi: 10.1007/s10552-012-0098-4. Epub 2012 Nov 18. PubMed PMID: 23160945; PubMed Central PMCID: PMC3529854. Impact Factor: 3.200. Q1: Public, Environmental & Occupational Health.
  68. L. von Karsa, J. Patnick, N. Segnan, W. Atkin, et al. European colorectal cancer screening guidelines working group (Peris M) European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. Endoscopy. 2013; 45 (1) 51-59. Impact Factor: 5.735. Q1: Gastroenterology & Hepatology.
  69. L Costas, E Papadopoulou, B Perez-Gomez, X Basagaña, F Alarcon, D Casabonne, Y Benavente, G Castaño-Vinyals, M Kogevinas, de Sanjosé S. Reliability of 2D:4D measurements using a direct method suitable for clinical settings. Personality and Individual Differences. 55 -3, pp. 339 -342. 2013
  70. Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in central and eastern europe and central Asia. Vaccine. Volume 31, supplement 7, H32–45 (31 December 2013). Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  71. Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russian Federation, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia. Vaccine. Volume 31, supplement 7, H46–58 (31 December 2013). Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  72. Baboci L, Boscolo-Rizzo P, Holzinger D, Bertorelle R, Biasini L, Michel A, Schmitt M, Spinato G, Bussani R, Alemany L, Tirelli G, Da Mosto MC, Del Mistro A, Pawlita M. Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J, 2013 Nov 12;10(1):334. Impact Factor: 2.092. Q3: Virology.
  73. De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine, 2013 31 Suppl 5:F32-46. Impact Factor: 3.492. Q2: Medicine, Research & Experimental.
  74. Robles C, Viscidi R, Malats N, Silverman DT, Tardon A, Garcia-Closas R, et al. Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. Int J Cancer 2013;133(3):597–603. Impact Factor: 6.198. Q1: Oncology.

European Commission

1. Organisme:  European Commission. 7th Framework Programme
Títol del projecte: Comparing Health Services interventions for the prevention of HPV-related cancer (CoheaHr)
Investigador principal: Bosch FX (Spain) (Coordinador: CJLM Meijer)
Co-investigadors: Castellsagué X, de Sanjosé S, Bruni L, Sedano A, Ibañez R, Roura R
Ref.: HEALTH 2013.3.1-1.
Import grup: 675.000,12€
Duració: : 2013-2018

2.
 Organisme: European Commission. 7th Framework Programme
Títol del projecte: HPV-AHEAD-Role of human papillomavirus infection and other co-factors in the aetiology of head and neck cancer in Europe and India
Investigador principal: Bosch FX
Co-investigadors: de Sanjosé S, Castellsagué X, Alemany L
Ref.: 282562
Import concedit: 200.958€
Duració: : 2011-2013

3.
 Organisme: European Commission
Títol del projecte: Supporting innovative learning approaches through Mobile Integration in the workpLacE - Oncology Nursing SMILEON
Investigador principal: Sedano A
Co-investigadors: Company A, Fernández P, Montserrat M
Ref.: 518383-LLP-2011- Leonardo-ES-LMP
Import concedit: 398.346€ (Import grup : 172.253€ ICO)
Duració: : 2011-2013

4.
 Organisme: European Commission. 7th Framework Programme
Títol del projecte: Health-economic modelling of PREvention strategies for HPV-related Diseases in European CounTries. PREHDICT
Investigador principal: Bosch FX
Co-investigadors: Castellsagué X, de Sanjosé S, Diaz M, Muñoz J, Bruni L, Brotons M
Ref.: 242061
Import concedit: Import grup: 398.702€
Duració: : 2009-2013

Govern d’Espanya 

5.
 Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III
Títol del projecte: Estudio internacional sobre la distribución de genotipos específicos del Virus del Papiloma Humano (VPH) en los cánceres de faringe y laringe
Investigador principal: Castellsagué X
Co-investigadors: Alemany L, Albero G, Guimerà N, Klaustermeier JE, Lloveras B, Alejo M, Clavero O
Ref.: PI081535
Import concedit: 183.920€

6. Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III
Títol del projecte: Modelo dinámico de transmisión de la infección por los VPHs 16 y 18. Implicaciones económicas y sanitarias en la población española según diferentes escenarios de vacunación.
Investigador principal: Díaz M
Co-investigadors: Kim JJ, Ibáñez R
Ref. PI11/02090
Import concedit: 67.429,67€
Duració:  : 2011-2013

7.
 Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III)
Títol del projecte: Detección de ADN del Virus del Papiloma Humano (VPH) en cánceres anogenitales en España. Estudio complementario a PREHDICT, proyecto europeo del VII Programa Marco.
Investigador principal: Bosch FX
Ref.: PI10/02995
Import concedit: 114.224€
Duració: : 2011-2013

8. Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III)
Títol del projecte:
 Ampliando el espectro de papilomavirus (VP) relacionados con el cáncer humano: detección y actividad biológica de VPH cutáneos y VP no humanos en los cánceres de cabeza y cuello
Investigador principal: Castellsagué X
Co-investigadors: Godínez J, Quiros B, Alemany L, Klaustermeier J y Alejo M
Ref.: PI11/02104
Import concedit: 156.128€
Duració: : 2011-2014

9.
 Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III)
Títol del projecte:
 El papel etiológico y pronóstico del Virus del Papiloma en pacientes con cáncer de orofaringe
Investigador principal: Bosch FX
Co-investigadors: Alemany L, Lloveras B, Esteban A, Maños A, Marí A, Bonfill T, Aguila A, García J, Gras JR
Ref.: PI11/02096
Import concedit: 413.820€
Duració: : 2011-2015

10.
 Organisme: Fondo de Investigación Sanitaria (Instituto de Salud Carlos III)
Títol del projecte: Factores de riesgo ambientales, infecciosos y genéticos asociados a la leucemia linfática crónica (LLC), en el marco del estudio Multi-Caso-Control (MCC-SPAIN)
Investigador principal: de Sanjosé S
Co-investigadors: Dierssen T, Costas L, Garcia M, Castaño G, Benavente Y, Gomez I,  Gonzalez Barca E, Robles C, Alonso ME, Casabonne D, Rios R, Vergara M, de Oliveira AC
 Ref.: PI11/01810
 Import concedit: 262.130,55€
Duració: : 2011–2014

11.
 Organisme: Ministerio de Ciencia e Innovación. Centro Superior de Investigación en Salud Pública. MICINN.
Títol del projecte: Biodiversidad y evolución de papillomaviruses.
Investigador principal: Bravo IG
Referència: CGL2010-16713 (subprograma BOS)
Co-investigadors:
Import concedit: 100.000€
Duració: : 2011 - 2013 

Grups d’investigació 

12.
 Organisme: Agencia de Gestión de Ayudas Universitarias y de Investigación (AGAUR, Generalitat de Catalunya)
Títol del projecte: Grupo consolidado de investigación - Grupo Virus y Cáncer – Ayudas a grupos de Investigación SGR 
Investigador principal: Bosch FX (Coordinador)
Co-investigadors: Castellsagué, X, Albero G, Alemany ME,  Bruni L, Díaz M,  Ibáñez R, Louie K, Roura E, Tous S, Klaustermeier JE, Esteban A, Florencia Y, Guimerà N, Berti L, Camon V, Clavero O, Vergara M, Company A, Guillen O, Muñoz J, Alejo M, Lloveras B, Muñoz N, Quint W, Quiros B, de Sanjosé S, Benavente Y,  Bravo IG, Brotons M, Serrano B, Puerta R, Félez M, Nicolás S, Pimenoff VN, Bedhomme S y Mengual B
Ref.: 2009 SGR 1026 
Import concedit: 70.720€
Duració: : 2009-2013  

13. Organisme: Agencia de Gestión de Ayudas Universitarias y de Investigación (AGAUR, Generalitat de Catalunya)
Títol del projecte: SGR - Grupo de investigación reconocido: EPILYMPH - Epidemiología de los linfomas.
Investigador principal: de Sanjosé S (Coordinadora)
Co-investigadors: Benavente Y, Domingo E, Alarcón F, Espinosa A, Enjuanes A, Campo E, Pujana MA, Estivill X, Robles C, Costas L, Fernández de Sevilla, González Barca, Casabonne D, Godínez JM, Rodriguez V y Mena M
Ref.: 2009 SGR 1465
Import concedit: 42.640€
Duració: : 2009-2013

14.
 Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III)
Títol del projecte:
 Redes Temáticas de Investigación Cooperativa en Salud. RTICCC
Investigador principal: Bosch FX 
Co-investigadors: Díaz M, Pareja L, Ribes J, Bravo IG, Gumà J, Clavero OE, Ibáñez R, Bruni L,  Sanz FX, Clèries R, Lloveras B, Company A, Muñoz J; Marcos Gragera R, Godínez JM, Camón V, Esteban A, Florencia Y, Tous S, Vergara M, Quirós B, Brotons M i Mena M
Ref.:    RD12/0036/0056
Import concedit:  81.592,50€ per any del projecte (renovable anual, previsió 4 anys)
Duració: : 2013-2016

15.
 Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III)
Títol del projecte: Redes Temáticas de Investigación Cooperativa en Salud. RTICCC Epidemiología
Investigador principal: Bosch FX (Coordinador grup)
Ref.:    RD06/0020/0095
Import concedit: 739.077,30€
Duració: : 2006-2013

16.
 Organisme: Fondo de Investigaciones Sanitarias (Instituto de Salud Carlos III)
Títol del projecte:
 CIBER en Epidemiología y Salud Pública. Grupo 36
Investigador principal: de Sanjosé S (Coordinadora grup)
Ref.: CIBERESP
Import concedit: 534.049,89 € (fins la data) 
Duració: : Inici 2007 – renovable anualment

Data d'actualització:  16.04.2014